The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Svechnikova E.V.

Lechebno-ozdorovitel'nyĭ tsentr "Eurofemme"

Zhufina S.E.

Polyclinic №1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia, 119002

Experience in the use of sekukinumab in a patient with severe extensive psoriasis vulgaris and psoriatic arthritis

Authors:

Svechnikova E.V., Zhufina S.E.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2018;17(3): 97‑102

DOI: 10.17116/klinderma2018173103

Read: 3908 times

Download PDF (RU)
Contact the author
Table of contents

EXPERIENCE IN THE USE OF SEKUKINUMAB IN A PATIENT WITH SEVERE EXTENSIVE PSORIASIS VULGARIS AND PSORIATIC ARTHRITIS
EXPERIENCE IN THE USE OF SEKUKINUMAB IN A PATIENT WITH SEVERE EXTENSIVE PSORIASIS VULGARIS AND PSORIATIC ARTHRITIS

To cite this article:

Svechnikova EV, Zhufina SE. Experience in the use of sekukinumab in a patient with severe extensive psoriasis vulgaris and psoriatic arthritis. Russian Journal of Clinical Dermatology and Venereology. 2018;17(3):97‑102. (In Russ.)
https://doi.org/10.17116/klinderma2018173103

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Search of diagnostic and prognostic biomarkers of immu­noinflammatory dermatoses by means of flow cyto­metry. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):170-177
Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xero­sis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):178-184
Chro­nic hidradenitis suppurativa: morbidity patterns and patients’ routing in Saint-Petersburg. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):255-260
Historical aspe­cts and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):284-292
Key specific tools for asse­ssment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):319-325
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):453-460
Persistence of skin process remi­ssion in patients with mode­rate and severe psoriasis vulgaris in application of neta­kimab: a five-year obse­rvational study resu­lts. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):462-468
Syne­rgistic effi­ciency of preformed physical factors and dupi­lumab in the treatment of poly­pous rhinosinusitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):16-23
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Abstract:

The article presents modern data on the treatment of psoriasis using genetically engineered biological agents and new aspects of the pathogenesis of psoriasis and comorbid conditions. We report a case of the effective treatment of a patient with severe extensive psoriasis vulgaris and psoriatic arthritis with secukinumab.

Keywords:

psoriasis
genetically engineered biological therapy
secukinumab

Authors:

Svechnikova E.V.

Lechebno-ozdorovitel'nyĭ tsentr "Eurofemme"

Zhufina S.E.

Polyclinic №1 of the Administrative Department of the President of the Russian Federation, Moscow, Russia, 119002

Close metadata

References:

  1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512-516. https://doi.org/10.1037/e664712010-005
  2. Kubanova AA, Kubanov AA, Melekhina LE, Bogdanova EV. Dermatovenereology in the Russian Federation. Results of 2014. Successes, achievements. The main ways of development. Herald dermatol venereol. 2015;4:109-115. (In Russ.)
  3. Dauden E, Castaneda S, Suarez C, Garcıa-Campayo J, Blasco AJ, Aguilar MD, Ferrandiz C, Puig L, Sa nchez-Carazo JL. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. 2015.
  4. Bakulev AL. The strategy of «treatment before the goal» in psoriasis. Topical issues of resistance to biological therapy. Vestn dermatol venereol. 2016;(5):32-38. (In Russ.)
  5. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.16. https://doi.org/10.1056/nejmra0804595
  6. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015;33:13-23. https://doi.org/10.1016/j.det.2014.09.002
  7. Lin AM, Rubin CJ, Khandpur R, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187:490-500. https://doi.org/10.4049/jimmunol.1100123
  8. Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015;34(6):1019-1023. https://doi.org/10.1007/s10067-015-2961-7
  9. Kolbinger F, et al. ADD 2015. San Francisco, CA (Poster 1264).
  10. Korotayeva TV. Prospects for the use of interleukin 17 inhibitors — a new class of drugs for targeted therapy of psoriatic arthritis. Nauch-prakt revmatol. 2016;54(3). (In Russ.)
  11. Strober B, Gottlieb A, Sherif B, et al. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017;76:655-661. https://doi.org/10.1016/j.jaad.2016.11.043
  12. Blauvelt А, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76:60-69. https://doi.org/10.1016/j.jaad.2016.08.008
  13. Kungurov NV, Zilberberg NV, Kokhan MM, Keniksfest YuV, Grishaeva EV. Experience of the use of the drug secukinumab therapy of severe resistant psoriasis. Leashing doctor. 2017 november;11:1-6. (In Russ.)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.